-
GenScript Dissolves Merger with CAR-T Specialist Legend Biotech, Reclassifies as Associated Company
•
GenScript Biotech Corporation (HKG: 1548), a comprehensive life science research and application service and product provider based in China, has announced the dissolution of its merger with Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell therapy. The decision to dissolve the merger was influenced by…
-
China’s NMPA Greenlights Pilot Plan for Phased Manufacturing of Biological Products
•
The National Medical Products Administration (NMPA) has given its stamp of approval to the “Pilot Work Plan for Phased Manufacturing of Biological Products,” a document that outlines a comprehensive framework for the phased production of certain innovative and urgently needed biological products through contract manufacturing. The plan, anticipated to be…
-
Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific
•
Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of its shares in Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853), according to a Bloomberg report. The company is said to be working with financial advisors to assess its minority stake in MicroPort after…
-
Dongcheng Pharma Moves to Enhance Portfolio with Acquisition of Rongcheng Medical’s GSA Injection
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its intention to acquire full rights to the 99mTc GSA Injection and GSA cold kit from domestic rival Rongcheng Medical Technology Wuxi Co., Ltd., for a purchase price of RMB 85 million (approximately USD 11.82 million). The 99mTc GSA…
-
Johnson & Johnson’s Akeega Approved in China as First Dual Action Tablet for mCRPC
•
Johnson & Johnson (J&J, NYSE: JNJ), a leading US pharmaceutical company, has announced that China’s National Medical Products Administration (NMPA) has granted indication approval for Akeega (niraparib and abiraterone acetate), to be taken with prednisone or prednisolone, for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2…
-
Everest Medicines’ Nefecon Approved in Taiwan for Primary IgAN Treatment
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received market approval from the Taiwan Food and Drug Administration for its targeted-release budesonide, Nefecon, for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. This approval allows for the use…
-
BeiGene’s Tevimbra Approved in China for NSCLC Patients as Neoadjuvant and Adjuvant Therapy
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading China-based biotechnology company, has announced that it has received market approval in China for its programmed death-1 (PD-1) inhibitor Tevimbra (tislelizumab). The National Medical Products Administration (NMPA) has granted approval for tislelizumab in combination with platinum-containing chemotherapy as both neoadjuvant…
-
Tianjin Municipality Unveils Plan to Boost Synthetic Biology and Biomanufacturing Innovation
•
The People’s Government of Tianjin Municipality has unveiled two significant implementation plans to bolster the bioeconomy and pharmaceutical outsourcing service industry within the region. The first plan, “Implementation Plan for Accelerating the Innovation of Synthetic Biology and Promoting the High Quality Development of the Biomanufacturing Industry in Tianjin,” aims to…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
